Company: NDRA
Filing Date: 2025-10-30
Form Type: 424B5
Source: 0001213900-25-103705
Chunk: 11

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-30
Form: 424B5
Chunk 11
---
.                                                                                                   |

| ● | Signal Detection: A “receive only” ultrasound transducer specifically designed and                                                     
 optimized for thermoacoustic imaging. The transducer sub-system detects thermoacoustic signals induced by the RF source within tissue. 
 The transducer assembly is connected to high-speed electronics for signal amplification, digitization, and processing.                 |

| ● | Computation and Display: The computer provides processing capability to both utilize the conventional                                       
 ultrasound data for navigation to the measurement site of interest, and the calculations required to convert digitized thermoacoustic       
 signals into estimates of fat content in liver tissue. The entire sub-system will reside in a single enclosure, on wheels, and sit adjacent 
 to the patient exam bed. A small digital touchscreen display is used for both operator input and the display of data.                       |

TAEUS platforms may provide two-dimensional imaging with a transducer composed of multiple receive elements. ENDRA is currently developing an improved version of its first-generation liver device. The RF source and applicator would be similar to those in the first-generation product, but the multi-element transducer would allow for multiple applications including reading tissue composition, response to thermoablative procedures, vascular flow, tissue perfusion, and other potential applications.

<div align='center'>S-6</div>

Recent Developments

On October 10, 2025, we entered into a securities
purchase agreement (the “Securities Purchase Agreement”) with certain accredited investors (the “Purchasers”)
pursuant to which the Company agreed to sell and issue to the Purchasers in a private placement offering (the “Private Placement”)
an aggregate of 744,340 shares (the “Shares”) of common stock, and/or prefunded warrants in lieu thereof (the “Prefunded
Warrants”), and warrants (the “Common Warrants”) to purchase an aggregate of up to 1,488,680 shares of common stock
at a per share exercise price of $6.32. Each share of common stock (or pre-funded warrant in lieu thereof) and accompanying warrants
were sold at a combined purchase price of $6.57. The Private Placement closed on October 15, 2025. The Company intends to use the majority
of the net proceeds from the Private Placement to establish the Company’s DAT strategy, with a portion for working capital purposes
including the pilot validation imaging study of the Company’s TAEUS liver device. Pursuant to the Securities Purchase Agreement,
the Company may spend up